司会：栁原 克紀 先生 長崎大学大学院医歯薬学総合研究科 病態解析・診断学分野（臨床検査医学）
演者：Patrick Murray, Ph.D. VP Global Medical Affairs; BD Life Sciences
In December 2019, infections with SARS-CoV-2 were first reported in China. In August 2021, more than 212 million cases and 4.4 million deaths due to this virus have been documented globally, with substantial under-reporting in countries without access to diagnostic tests. SARS-CoV-2 is one of three highly virulent coronaviruses and the only one to reach global spread. Because of the wide dissemination of this virus and the ability of RNA viruses to rapidly mutate, 4 strains of the original virus have been labeled variants of concern; that is, variants where there is evidence of increased transmissibility, more severe disease, reduction in antibody neutralization, or diagnostic failures. The Delta variant is the predominant circulating strain in many countries, 2- to 4-fold more infectious that the parent strain of virus, and able to partially evade immunity based on prior viral infection or vaccination. Control of infections with SARS-CoV-2 have been accomplished with surface disinfection, social distancing, use of well-designed mask and eye shield, vaccination, and diagnostic testing of symptomatic individuals and contacts of infected patients. Failures in compliance with infection control practices and access to both vaccines and diagnostics have resulted in the continued outbreaks of infections and mortality, and the associated social and economic disruptions. This discussion will summarize how we can apply the lessons we have learned over the last 20 months to solving today’s Covid-19 problems.